Ahmed Abdelwahed was the one who could best challenge Topi Raitanen in the EC final of 3,000 meters hurdles. Now it is clear that the Italian gave a positive doping test for meldonium in connection with the championship in Munich.
It’s the Italian newspaper La Repubblica which draws attention to the fact that the silver medalist Abdelwahed tested positive.
Abdelwahed was a gold candidate in the 3,000 meter steeplechase final, but had to give up on the last lap when Topi Raitanen sprinted past. In Munich, Abdelwahed tested positive for meldonium, known as a heart drug.
The Italian has responded to the news on his Instagram account.
“I have not even heard of meldonium until I was told that it was found in my sample. I have never used it, so now I am trying to understand how it could have ended up in my urine,” wrote the Italian.
Raitanen: “Good that the doping work is working”
Yle Urheilu caught Raitanen, who learned about the case only a moment earlier.
– I haven’t had time to take a closer look at the case, so I don’t know how far the process has progressed. On the one hand, it’s fun that I managed to beat him on the track and experience that moment.
– For our own part, the denomination will not change if the process continues. It is good that the doping work is working. But it doesn’t sound good that a fellow competitor has ended up in this situation, Raitanen thinks.
Abdelwahed is familiar to Raitanen from before. In 2017, the Italian took EC silver in the U23 EC, Raitanen was fourth in the same race.
– Of course it surprises. There will surely be more news about the case in the coming weeks and months, then we will know what has happened. It’s a shame for the sport.
A few years ago, meldonium was in the news when scores of Russian athletes became addicted to the substance. Swedish running star Abeba Aregawi and tennis player Maria Sharapova who tested positive for meldonium.
This is Auto Posted article collected article from different sources of internet, EOS doesn’t take any responsibilities of this article. If you found something wrong in this article, please tell us.